BIOEDGE

Biological EDGE

Buy Now

“Meticulous research. Penetrating analysis. A solid framework for change.”  — Dr. Michael J. Krentz

Biological EDGE

Biohacking Starts With NO

Buy Now

“I used to override my body. Now I listen. The difference is stunning.”— Michael Broder

Biohacking Starts With NO
Regenerative Therapies

Regenerative Therapies Library

Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.

AllLibraryArticlesPresentationsSpotlightsNews

Showing 145–155 of 155

Longevity.TechnologyApr 1, 2026

20/20 BioLabs expands longevity test with kidney risk tech

20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.

LT WireFeb 4, 2026

Acorn Biolabs treats first patients in randomized hair regeneration trial

Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.

LT WireFeb 7, 2026

PrimeGen US to merge with DT Cloud Star in $1.5B SPAC deal

PrimeGen US, a regenerative medicine company developing stem cell and exosome therapies, is merging with a SPAC at a $1.5 billion valuation to advance clinical trials for acute liver injury and related conditions. The capital infusion targets acceleration of regulatory pathways and commercialization of cell-based treatments grounded in two decades of proprietary stem cell research.

Longevity.TechnologyFeb 12, 2026

Genflow reveals early data from SIRT6 gene therapy trial in dogs

Genflow's SIRT6 gene therapy demonstrated superior survival and functional improvements in aged beagles across multiple endpoints, including muscle preservation, frailty reduction, and quality of life measures. This interim data from a proof-of-concept trial establishes preliminary evidence that SIRT6 activation may mitigate age-related functional decline, with potential implications for human therapeutic development.

Wiley Aging CellMar 24, 2026

Role of Succinate Dehydrogenase in Age‐Related Th17 Inflammation

Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.

LifeSpan.ioApr 10, 2026

Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice

Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.

LT WireApr 22, 2026

BioAge reports positive Phase 1 data for BGE-102

BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.

LT WireMay 13, 2026

Lysoway begins Phase 1 trial for neurodegenerative disease treatment

Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.

LifeSpan.ioMar 24, 2026

BioAge Labs Provides Business Updates

BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.

Longevity.TechnologyApr 9, 2026

United Therapeutics receives RMAT designation for Miroliver ELAP

United Therapeutics received FDA Regenerative Medicine Advanced Therapy designation for Miroliver ELAP, a bioengineered external liver assist device combining a decellularized porcine scaffold seeded with human endothelial and hepatic cells. This designation accelerates development of a bridge therapy for acute liver failure, where 30% of patients currently die due to organ shortage despite potential for spontaneous recovery.

Wiley Aging CellMar 27, 2026

Gut Luminal Exosomes in Young and Old Mice: Multi‐Omic Characteristics and Regulation of Gut Permeability

Exosomes in the gut lumen change composition with age, with those from older mice directly impairing barrier integrity and insulin sensitivity in younger recipients, while young exosomes reverse these effects in older mice. This identifies a specific molecular mechanism linking intestinal barrier dysfunction to metabolic aging.